Research

NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)

The purpose of this notice of funding opportunity (NOFO) is to encourage researchers from diverse backgrounds to work with their institutions to submit applications for research projects within the mission of either NIAID or NIDDK. This NOFO seeks to support either (a) a New Investigator (NI), who has not previously competed successfully for substantial, independent funding from NIH, or (b) an 'At-Risk' investigator, who had prior support as a PD/PI on a substantial independent research award and unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.

Eligible candidates will identify with one of the two categories below:

1. New Investigator (NI)

For the purpose of this NOFO, an investigator is considered a New Investigator (NI; https://grants.nih.gov/policy/early-investigators/index.htm) if they have not competed successfully for substantial, NIH independent funding from NIH. A "substantial" research award is a research grant award excluding smaller grants that maintain Early Stage Investigator (ESI)/NI status (see full list of awards here: https://grants.nih.gov/policy/early-investigators/list-smaller-grants.htm). PD/PIs of NIH Training-Related and Mentored Career Awards are still considered New Investigators if the NIH awards are in any of the following categories: fellowships (F awards), individual or institutional career awards (K awards), and loan repayment contracts (L30, L32, L40, L50, L60). Appointees who have received support from any NIH training grants (T32, T34, T35, T90, D43) are also considered New Investigators.

OR

2. At-Risk Investigator

For the purpose of this NOFO, an investigator is considered an At-Risk Investigator if they have had prior support as a Principal Investigator on a substantial independent research award and, unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year. A "substantial" research award is a research grant award excluding smaller grants that maintain ESI/NI status

Opportunity ID
a129d9dd-dacf-45b6-8c19-f2f1552f7976
External Deadline
02/05/2025 (Anticipated)

NLN Nursing Education Research Grants

Research activities advance the NLN's goal of taking the "lead in the conduct of research that informs and promotes evidence-based teaching, advances the science of nursing education, and provides and interprets data about nursing education and the nurse educator workforce." Over the past decade, the NLN has provided funding of more than $1 million dollars for research in nursing education.

NLN Research in Nursing Education Grants (maximum grant up to $30,000)
Mary Anne Rizzolo Doctoral Research Award ($2,500 award for doctoral student)
Edmund J.Y. Pajarillo Health Informatics and Innovation Collaborative Research Award ($2,500 award for graduate student)
External Deadline
02/01/2025(Anticipated)

Agilent Early Career Professor Award

The purpose of the Agilent Early Career Professor Award is to:

Promote and encourage excellent research enabling measurements of importance to Agilent Technologies and the world
Establish strong collaborative relationships between Agilent researchers and leading professors early in their career
Build the prominence of Agilent as a sponsor of university research

Focus Topic: Contributions to environmental sustainability through development of green analytical technologies, methods, or laboratory working environments.
Opportunity ID
a1768123-848f-4971-95ff-d1d75de8f0f3
External Deadline
02/13/2025 (Anticipated)

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
This Funding Opportunity Announcement does not accept applications proposing clinical trials.
Opportunity ID
958f40d9-3f44-4b36-bad2-d1d75de8f0f3
External Deadline
12/23/2025(Anticipated)

Faculty Starter Grant - Drug Discovery Targets and Pathways

The PhRMA Foundation Faculty Starter Grant in Drug Discovery Targets and Pathways offers financial support to individuals beginning independent careers in drug discovery research at the faculty level at an accredited U.S. university.

Successful drug discovery involves the innovative application and integration of multiple scientific disciplines to create efficacious, safe, and differentiated treatment options for patients. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease. 

Research topics could include, but are not limited to:  
Genomics and Proteomics 
Cellular and Molecular Biology 
Design and Generation of Pharmacological Tools  
In Vitro and/or In Vivo Pharmacology 
Protein Biochemistry 
Molecular Modelling 
Structural Biology 
Cell Imaging 
Single Cell Analysis 
Artificial Intelligence and Computational Approaches 
Projects that focus exclusively on single aspects such as identification of and development of assays for single targets, chemical probes, biomarkers, chemical library screening, or diagnostics will not be considered for review. Project aims should have a high likelihood of completion in the award timeframe.
Opportunity ID
37f799da-4d95-4d4e-82f9-d1d75de8f0f3
External Deadline
02/01/2025(Anticipated)

Faculty Starter Grant - Translational Medicine

Translational medicine is a scientific discipline focused on turning observations in the laboratory, clinic, and community into medicines, diagnostics, or other interventions that improve human health.

Translational medicine fosters a patient-focused research cycle that stretches from the lab bench to the patient bedside and back to the lab again. This includes adapting basic research discoveries in cells, tissues, and animals for application in humans and then taking the knowledge of what did and didn’t work in the clinic back to the bench.

Given the breadth of the discipline, the PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.

Applicants should work with clinical collaborators to identify unmet clinical needs. Proposals should integrate innovative technologies, with advanced biological, chemical, diagnostic, and pharmacological sciences and engineering methodologies in areas that include but not are limited to:
Genetics (Molecular, Pharmaco-, Population, Medical)
Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative)
Systems (Biology and Pharmacology)
Pathways and Networks
Integrative Biology
Modeling and Simulation
Target Identification and Validation
Biomarker Identification and Validation
Molecular Epidemiology
Imaging
Disease Modeling
Opportunity ID
862bfcf1-03b3-481a-9ae6-d1d75de8f0f3
External Deadline
02/01/2025(Anticipated)

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Components of Participating Organizations:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Human Genome Research Institute (NHGRI)
Opportunity ID
f9a649d9-5afb-4ed7-8a8e-d1d75de8f0f3
External Deadline
02/16/2025 (Anticipated)

OREF New Investigator Grant

The New Investigator Grant advances the scientific training of the next generation of orthopaedic physician-scientists by providing seed and start-up funding for promising research projects.Residents, fellows, and orthopaedic surgeons having completed formal training within the last four years may apply. View the RFA on proposalCentral for complete eligibility requirements.
Opportunity ID
2060d9e9-0c95-4782-bdbf-d1d75de8f0f3
External Deadline
8/12/2025 (Anticipated)

G. Harold & Leila Y. Mathers Foundation: 2023 Basic & Translational Research Grants

Limit: 4 // PIs:
A. Chignalia (Anesthesiology)
Y. Wang (College of Medicine - Tucson)
G. Sutphin (Molecular & Cellular Biology)
J. Streicher (College of Medicine - Tucson)
 

The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. The foundation’s grants program seeks to support basic science, ideally with potential translational applications. Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support. 

For many years the Foundation has enjoyed special recognition in the research community for supporting “basic” scientific research, realizing that true transformative breakthroughs usually occur after a thorough understanding of the fundamental mechanisms underlying natural phenomena. More recently, and with the advent of newer investigative methodologies, technology, and tools, the Foundation now embraces innovative translational research proposals.

The grant duration must be three years. The budget should be reasonable based on the aims of the project. Indirect costs may not exceed 10%. Preliminary Budgets are required during the LOI phase. A detailed budget justification is not required until the proposal phase.  The Foundation’s grant award is not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab and is intended only to support the actual investigation. The Foundation assumes and expects that capital equipment must be provided by the research institution or university.
 

Application Guidance:

  • Grant budgets cannot exceed $600-750K 
  • The Foundation primarily supports basic science, ideally with potential translational applications.
  • Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.
  • Covid-19-related research projects (aims or sub-aims) will not be considered for support.
  • Medical imaging technology-related projects and/or electrical engineering technology development projects will not be considered for support.
  • Plant Biology Research, Oceanography, Space Exploration. and Global warming-related research will not be considered for support.
  • As technology continues to advance, it is apparent that investigations in the area of basic science and translational research may become more and more reliant on collaborative, interdisciplinary projects. It is important to note that any interdisciplinary project proposals may require additional information regarding the collaborator(s)’ achievements and relevant expertise.
  • Feedback for declined LOI Requests will not be provided; LOIs or Formal Proposals that have been declined should not be resubmitted at a later date for consideration.
  • Renewal applications for the same or related research will not be accorded priority consideration. It is strongly advised that any re-application for grant renewal consider a new direction based on prior research or emphasize some new potential translational aspects and not merely an extension of previously funded research.
  • Requests for funding previously federally supported research and/or applications pending federal approval will not be accorded priority consideration.
  • Requests for support of clinical trials or drug discovery will not be approved. The Foundation will not support projects which we consider pre-clinical drug development.

 

Funding Type
Internal Deadline
External Deadline
11/17/2023 - Required registration

DOS SFOP0010109: 2024 FY24 Protecting Semiconductor and CHIPS Technology

Limit: 1  // PI: L. Folks (Semiconductor Strategy)  

 

Only one application per institution is allowed.

In support of the Department of State implementation of the International Technology Security and Innovation (ITSI) Fund, appropriated under the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act of 2022, ISN/CTR will sponsor activities to secure semiconductor supply chains and mitigate risks that some uses of advanced semiconductors can pose to national and international security.

 

The Department of State’s Bureau of International Security and Nonproliferation, Office of Cooperative Threat Reduction (ISN/CTR) is pleased to announce an open competition for assistance awards through this Notice of Funding Opportunity (NOFO). ISN/CTR sponsors foreign assistance activities funded by the Nonproliferation, Antiterrorism, Demining and Related Programs (NADR) and other accounts, and focuses on mitigating weapons of mass destruction (WMD) and WMD-related delivery systems proliferation and security threats from non-state actors and proliferator states. An underlying aim of all ISN/CTR’s efforts is long-term sustainability to maximize programmatic impact while minimizing the need for foreign partners to rely on outside financial or technical assistance.

Funding Type
Internal Deadline
External Deadline
01/31/2024